NCT04690231View on ClinicalTrials.gov

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

NACompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

March 1, 2021

Study Completion Date

June 1, 2021

Conditions
Effect of DrugToxicity, DrugSecondary Resistance
Interventions
DRUG

Apatinib Mesylate

apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3

DRUG

ifosfamide and etoposide

ifosfamide and etoposide

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Shougang Hospital

OTHER

lead

Peking University People's Hospital

OTHER

NCT04690231 - Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma | Biotech Hunter | Biotech Hunter